Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,666.26
(
-0.74%
)
US TECH 100
24,012.40
(
-0.50%
)
Dow Jones
46,510.93
(
-1.03%
)
Brent Oil
104.66
(
3.98%
)
Bitcoin
71,750.86
(
-2.96%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 134488

Friday, 01/06/2012 5:21:55 PM

Friday, January 06, 2012 5:21:55 PM

Post# of 257253
BIIB/ELN/MNTA/etc—Thanks for your post. Scangos’ comment about generic Copaxone is a throwaway devoid of information, but the stuff about Tysabri is somewhat interesting:

We would recommend that patients who are JCV negative get tested each year. We would recommend they stay on if negative. Even for a long period after conversion the risk is low.

What is the frequency of JCV testing specified in the FDA and EMA labels?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now